To Our Valued Clients, Partners, and Friends, We are pleased to announce the appointment of Dr. ZhaoBo Gao as Chief Operating Officer (COO) of JYMed Peptide. Dr. Gao brings more than 20 years of successful experience in...
Our Blog
March 2026: Key News in GLP-1 & Peptide Drugs
Date: March 2026 | 1. FDA Crackdown on Unapproved Compounded GLP-1 Products The U.S. FDA issued 30 warning letters to telehealth companies and compounding pharmacies marketing unapproved compounded GLP-1 products (e.g., semaglutide, tirzepatide) with false efficacy...
JYMed Peptide Receives FDA DMF Acknowledgment for Semaglutide API Manufactured Under a New Process
JYMed is pleased to announce that the U.S. Food and Drug Administration has acknowledged receipt of a new Type II Drug Master File for semaglutide API manufactured under a new process. FDA acknowledgment letter for JYMed’s Type II DMF filing for semaglutide API...
Rare Disease Day
A condition may be “rare,” but no person should feel invisible.At JY MedTech, we recognize the resilience of the rare disease community and the importance of continued collaboration across science and healthcare.Today, we stand with patients, families, advocates, and...
Happy Lunar New Year 2026 🧧
From all of us at JYMed Peptide, we wish our customers, partners, and friends around the world a joyful Lunar New Year, filled with good health, happiness, and success. Thank you for your continued trust and collaboration. We look forward to supporting your projects...
Sustainable Peptide Manufacturing: How Green Chemistry Is Shaping the Future of Pharma
Why Sustainable Peptide Manufacturing Is Becoming Essential in Pharma Sustainable peptide manufacturing is rapidly becoming a priority in the pharmaceutical industry. The rapid global expansion of peptide therapeutics in metabolic and chronic disease treatment is...
Major regulatory milestone, JYMed Achieves Preliminary K-DMF Registration for Semaglutide API in South Korea
As part of our semaglutide program, JY MedTech has successfully completed the registration of the semaglutide active pharmaceutical ingredient (API) Korean Drug Master File (K-DMF) in South Korea. The API registration certificate has been issued by the Korean Ministry...
JYMed Peptide Awarded EcoVadis
JYMed Peptide has been independently assessed by EcoVadis Bronze Medal Dec 2025, a globally recognized sustainability ratings provider used across supply chains. In the December 2025 assessment, JYMed Peptide achieved an overall score of 70/100, placing us in the 83rd...
Peptide Synthesis Technologies Explained: How JYMed Optimizes SPPS, LPPS, and Hybrid Platforms
Innovation at the Core of Peptide Manufacturing Advanced peptide synthesis technologies are essential to meeting the growing demand for complex peptides in metabolic, oncological, and cosmetic therapeutics. Achieving reliable and scalable production requires mastery...








